180 related articles for article (PubMed ID: 35653624)
1. Identification and Validation of Serum CST1 as a Diagnostic Marker for Differentiating Early-Stage Non-Small Cell Lung Cancer from Pulmonary Benign Nodules.
Lai Y; Wang Y; Wu Y; Wu M; Xing S; Xie Y; Chen S; Li X; Zhang A; He Y; Li H; Dai S; Wang J; Lin S; Bai Y; Du H; Liu W
Cancer Control; 2022; 29():10732748221104661. PubMed ID: 35653624
[TBL] [Abstract][Full Text] [Related]
2. Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma.
Yang J; Luo G; Li C; Zhao Z; Ju S; Li Q; Chen Z; Ding C; Tong X; Zhao J
BMC Cancer; 2022 May; 22(1):589. PubMed ID: 35637432
[TBL] [Abstract][Full Text] [Related]
3. [Clinical value of tumor-associated autoantibodies in diagnosis of early non-small cell lung cancer].
Ren Z; Ding HM; Qian X; Pan SY
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1426-1434. PubMed ID: 34963239
[No Abstract] [Full Text] [Related]
4. [Evaluation of the application value of seven tumor-associated autoantibodies in non-small cell lung cancer based on machine learning algorithms].
Hao Y; Wu LN; Lyu YT; Liu YZ; Qin XS; Zheng R
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Nov; 57(11):1827-1838. PubMed ID: 38008573
[No Abstract] [Full Text] [Related]
5. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
[TBL] [Abstract][Full Text] [Related]
6. New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?
Li M; Zhang Y; Jiang L; Li Y; Li G; Zhou J; Yang C; Li X; Qu W; Chen Y; Chen Q; Wang S; Xing J; Huang H
Neoplasma; 2022 May; 69(3):729-740. PubMed ID: 35471981
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Serum MicroRNA21 and Tumor Markers in Diagnosis of Early Non-Small Cell Lung Cancer.
Sun M; Song J; Zhou Z; Zhu R; Jin H; Ji Y; Lu Q; Ju H
Dis Markers; 2016; 2016():3823121. PubMed ID: 26880855
[TBL] [Abstract][Full Text] [Related]
8. Exosomal LncRNA RP5-977B1 as a novel minimally invasive biomarker for diagnosis and prognosis in non-small cell lung cancer.
Min L; Zhu T; Lv B; An T; Zhang Q; Shang Y; Yu Z; Zheng L; Wang Q
Int J Clin Oncol; 2022 Jun; 27(6):1013-1024. PubMed ID: 35482171
[TBL] [Abstract][Full Text] [Related]
9. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
Hang ZQ; Zheng MF; Huang JH
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
[TBL] [Abstract][Full Text] [Related]
10. Elevated expression of CST1 promotes breast cancer progression and predicts a poor prognosis.
Dai DN; Li Y; Chen B; Du Y; Li SB; Lu SX; Zhao ZP; Zhou AJ; Xue N; Xia TL; Zeng MS; Zhong Q; Wei WD
J Mol Med (Berl); 2017 Aug; 95(8):873-886. PubMed ID: 28523467
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
12. The Clinical Significance of Serum MASP-2 and IDH1 in the Early Diagnosis of Non-Small Cell Lung Cancer.
Chen Y; Wu ED; Ma S; Bai WQ; Yin YJ; Shi GL
Clin Lab; 2020 Nov; 66(11):. PubMed ID: 33180422
[TBL] [Abstract][Full Text] [Related]
13. Detection of circulating exosomal miR-17-5p serves as a novel non-invasive diagnostic marker for non-small cell lung cancer patients.
Zhang Y; Zhang Y; Yin Y; Li S
Pathol Res Pract; 2019 Aug; 215(8):152466. PubMed ID: 31146974
[TBL] [Abstract][Full Text] [Related]
14. Identification of Circulating miR-762 as a Novel Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer.
Chen L; Li Y; Lu J
Technol Cancer Res Treat; 2020; 19():1533033820964222. PubMed ID: 33317398
[TBL] [Abstract][Full Text] [Related]
15. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of the cysteine protease inhibitor, cystatin SN, contributes to cell proliferation and cathepsin inhibition in gastric cancer.
Choi EH; Kim JT; Kim JH; Kim SY; Song EY; Kim JW; Kim SY; Yeom YI; Kim IH; Lee HG
Clin Chim Acta; 2009 Aug; 406(1-2):45-51. PubMed ID: 19463800
[TBL] [Abstract][Full Text] [Related]
17. Identification of cystatin SN as a novel biomarker for pancreatic cancer.
Jiang J; Liu HL; Liu ZH; Tan SW; Wu B
Tumour Biol; 2015 May; 36(5):3903-10. PubMed ID: 25577248
[TBL] [Abstract][Full Text] [Related]
18. Cystatin SN neutralizes the inhibitory effect of cystatin C on cathepsin B activity.
Kim JT; Lee SJ; Kang MA; Park JE; Kim BY; Yoon DY; Yang Y; Lee CH; Yeom YI; Choe YK; Lee HG
Cell Death Dis; 2013 Dec; 4(12):e974. PubMed ID: 24357805
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Diagnostic Value of CTC and CTDNA in Early Lung Cancer.
Hongwei Yao ; Lixin Wen ; Ziyan Li ; Chunwei Xia
Cell Mol Biol (Noisy-le-grand); 2023 Jun; 69(6):57-62. PubMed ID: 37605590
[TBL] [Abstract][Full Text] [Related]
20. Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer.
Bai Y; Shen W; Zhu M; Zhang L; Wei Y; Tang H; Zhao J
J Cell Biochem; 2019 Jan; 120(1):105-114. PubMed ID: 30216488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
